Biopsy after ablation: a new way to catch hidden cancer?

NCT ID NCT04143516

Recruiting now Knowledge-focused Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether taking a needle biopsy right after a tumor ablation procedure for liver metastases can detect cancer cells that survived the treatment. The results could help doctors decide if more treatment is needed right away. The study also looks at imaging and genetic markers to improve future care. About 200 adults with liver metastases that are small (3 cm or less) and show up on a PET scan are being enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could improve how doctors decide on retreatment after liver tumor ablation, potentially leading to better outcomes for patients with liver metastases.
What could go wrong: This is an early-to-mid-stage trial with only 200 participants. The biopsies carry risks like bleeding or infection, and the findings may not apply to all patients or tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER METASTASES

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.